Neurotensin is a tridecapeptide originally identified in extracts of bovine hypothalamus. This peptide has a close anatomical and functional relationship with the mesocorticolimbic and nigrostriatal dopamine system. Neural circuits containing neurotensin were originally proposed to play a role in the mechanism of action of antipsychotic agents. Additionally, neurotensin-containing pathways were demonstrated to mediate some of the rewarding and/or sensitizing properties of drugs of abuse.
This review attempts to contribute to the understanding of the role of neurotensin and its receptors in drug abuse. In particular, we will summarize the potential relevance of neurotensin, its related compounds and neurotensin receptors in substance use disorders, with a focus on the preclinical research.
AgnatiLFFuxeKBenfenatiF (1983) Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites. Acta Physiol Scand119: 459–461.
2.
AntonelliTFuxeKTomasiniMC (2007a) Neurotensin receptor mechanisms and its modulation of glutamate transmission in the brain: Relevance for neurodegenerative diseases and their treatment. Prog Neurobiol83: 92–109.
3.
AntonelliTTomasiniMCFournierJ (2008) Neurotensin receptor involvement in the rise of extracellular glutamate levels and apoptotic nerve cell death in primary cortical cultures after oxygen and glucose deprivation. Cereb Cortex18: 1748–1757.
4.
AntonelliTTomasiniMCFuxeK (2007b) Receptor-receptor interactions as studied with microdialysis. Focus on NTR/D2 interactions in the basal ganglia. J Neural Transm114: 105–113.
5.
BergerBGasparPVerneyC (1992) Colocalization of neurotensin in the mesocortical dopaminergic system. Restricted regional and laminar distribution in rat, lack of colocalization in human. Ann NY Acad Sci668: 307–310.
6.
BetancurCCabreraRDe KloetER (1998) Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine. Neuropsychopharmacology19: 322–332.
7.
BinderEBKinkeadBOwensMJ (2001) Neurotensin and dopamine interactions. Pharmacol Rev53: 453–486.
8.
BlackburnADewarKBaucoP (2004) Excitotoxic lesions of the prefrontal cortex attenuate the potentiation of amphetamine-induced locomotion by repeated neurotensin receptor activation. Brain Res998: 184–193.
9.
Borroto-EscuelaDORavaniATarakanovAO (2013) Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers. Biochem Biophys Res Commun435: 140–146.
10.
BosePRompréPPWarrenRA (2015) Neurotensin enhances glutamatergic EPSCs in VTA neurons by acting on different neurotensin receptors. Peptides73: 43–50.
11.
BottoJMGuillemareEVincentJP (1997) Effects of SR 48692 on neurotensin-induced calcium-activated chloride currents in the Xenopus oocyte expression system: Agonist-like activity on the levocabastine-sensitive neurotensin receptor and absence of antagonist effect on the levocabastine insensitive neurotensin receptor. Neurosci Lett223:193–196.
12.
BoulesMFredricksonPRichelsonE (2006) Bioactive analogs of neurotensin: Focus on CNS effects. Peptides27: 2523–2533.
13.
BoulesMLiZSmithK (2013) Diverse roles of neurotensin agonists in the central nervous system. Front Endocrinol4: 36.
14.
BoulesMMcMahonBWangR (2003) Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier. Brain Res987: 39–48.
15.
BoulesMOliverosALiangY (2011) A neurotensin analog, NT69L, attenuates intravenous nicotine self-administration in rats. Neuropeptides45: 9–16.
16.
BoulesMShawAFredricksonP (2007) Neurotensin agonists: Potential in the treatment of schizophrenia. CNS Drugs21: 13–23.
17.
BoulesMWarringtonLFauqA (2001) A novel neurotensin analog blocks cocaine- and D-amphetamine-induced hyperactivity. Eur J Pharmacol426: 73–76.
18.
BoulesMMFredricksonPMuehlmannAM (2014) Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders. Behav Sci4: 125–153.
19.
CácedaRBinderEBKinkeadB (2012) The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion. Schizophr Res136: 88–95.
20.
CácedaRKinkeadBNemeroffCB (2006) Neurotensin: Role in psychiatric and neurological diseases. Peptides27: 2385–2404.
21.
CampbellADErwinVG (1993) Chronic ethanol administration downregulates neurotensin receptors in long- and short-sleep mice. Pharmacol Biochem Behav45: 95–106.
22.
CarrawayRLeemanSE (1973) The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem248: 6854–6861.
23.
CarrawayRLeemanSE (1976) Characterization of radioimmunoassayable neurotensin in the rat. Its differential distribution in the central nervous system, small intestine and stomach. J Biol Chem251: 7045–7052.
24.
CastiPMarcheseGCasuG (2004) Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice. Neuropharmacology47: 128–135.
25.
CostaFGFrussa-FilhoRCanterasNS (2007) Blockade of neurotensin receptors during amphetamine discontinuation indicates individual variability. Neuropeptides41: 83–91.
26.
CostaFGFrussa-FilhoRFelicioLF (2001) The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice. Eur J Pharmacol428: 97–103.
27.
DobnerPRBarberDLVilla-KomaroffL (1987) Cloning and sequence analysis of cDNA for the canine neurotensin/neuromedin N precursor. Proc Natl Acad Sci USA84: 3516–3520.
28.
EhlersCLSomesCLiTK (1999) Neurontensin studies in alcohol naive, preferring and non-preferring rats. Neuroscience93: 227–236.
29.
ElliottPJNemeroffCB (1986) Repeated neurotensin administration in the ventral tegmental area: Effects on baseline and D-amphetamine-induced locomotor activity. Neurosci Lett68: 239–244.
30.
ErwinVGSuNC (1989) Neurotensin and ethanol interactions on hypothermia and locomotor activity in LS and SS mice. Alcohol Clin Exp Res13: 91–94.
31.
ErwinVGMarkelPDJohnsonTE (1997) Common quantitative trait loci for alcohol-related behaviors and central nervous system neurotensin measures: Hypnotic and hypothermic effects. J Pharmacol Exp Ther280: 911–918.
32.
FadelJDobnerPRDeutchAY (2006) Amphetamine-elicited striatal Fos expression is attenuated in neurotensin null mutant mice. Neurosci Lett402: 97–101.
33.
FatigatiMDAndersonRMRompréP (2000) Effects of prefrontal cortex microinjection of neurotensin-(8-13) on midbrain dopamine and non-dopamine cell firing. Brain Res876: 196–200.
34.
FeifelDMelendezGMurrayRJ (2008) The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance. Psychopharmacology200: 197–203.
35.
FelszeghyKEspinosaJMScarnaH (2007) Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference. Neuropsychopharmacology32: 2601–2610.
36.
FenuSSpinaLRivasE (2006) Morphine-conditioned single-trial place preference: Role of nucleus accumbens shell dopamine receptors in acquisition, but not expression. Psychopharmacology187: 143–153.
37.
FerraroLBeggiatoSBorroto-EscuelaDO (2014) Neurotensin NT1-dopamine D2 receptor-receptor interactions in putative receptor heteromers: Relevance for Parkinson’s disease and schizophrenia. Curr Protein Pept Sci15: 681–690.
38.
FerraroLTomasiniMCBeggiatoS (2009) Emerging evidence for neurotensin receptor 1 antagonists as novel pharmaceutics in neurodegenerative disorders. Mini Rev Med Chem9: 1429–1438.
39.
FerraroLTomasiniMCFuxeK (2007) Mesolimbic dopamine and cortico-accumbens glutamate afferents as major targets for the regulation of the ventral striato-pallidal GABA pathways by neurotensin peptides. Brain Res Rev55: 144–154.
40.
FerraroLTomasiniMCMazzaR (2008) Neurotensin receptors as modulators of glutamatergic transmission. Brain Res Rev58: 365–373.
41.
FilipMSiwanowiczJ (2001) Implication of the nucleus accumbens shell, but not core, in the acute and sensitizing effects of cocaine in rats. Pol J Pharmacol53: 459–466.
42.
FrankelPSHoonakkerAJAlburgesME (2011) Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia. J Pharmacol Exp Ther336: 809–815.
FredricksonPBoulesMYerburyS (2003a) Novel neurotensin analog blocks the initiation and expression of nicotine-induced locomotor sensitization. Brain Res979: 245–248.
45.
FredricksonPBoulesMYerburyS (2003b) Blockade of nicotine-induced locomotor sensitization by a novel neurotensin analog in rats. Eur J Pharmacol458: 111–118.
46.
FryeGDLuttingerDNemeroffCB (1981) Modification of the actions of ethanol by centrally active peptides. Peptides2: S99–106.
47.
FuxeKO’ConnorWTAntonelliT (1992) Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum. Proc Natl Acad Sci USA89: 5591–5595.
48.
FuxeKMarcellinoDRiveraA (2008) Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res Rev58: 415–452.
49.
GeislerSBérodAZahmDS (2006) Brain neurotensin, psychostimulants and stress-emphasis on neuroanatomical substrates. Peptides27: 2364–2384.
GlimcherPWGiovinoAAHoebelBG (1987) Neurotensin self-injection in the ventral tegmental area. Brain Res403: 147–150.
52.
GlimcherPWMargolinDHGiovinoAA (1984) Neurotensin: A new ‘reward peptide’. Brain Res291: 119–124.
53.
HallFSCentenoMPeronaMT (2012) Effects of neurotensin gene knockout in mice on the behavioral effects of cocaine. Psychopharmacology219: 35–45.
54.
HansonGRHoonakkerAJAlburgesME (2012) Response of limbic neurotensin systems to methamphetamine self-administration. Neuroscience203: 99–107.
55.
HedouGFeldonJHeidbrederCA (1999) Effects of cocaine on dopamine in subregions of the rat prefrontal cortex and their efferents to subterritories of the nucleus accumbens. Eur J Pharmacol372: 143–155.
56.
HeimerLZahmDSChurchillL (1991) Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience41: 89–125.
57.
HertelPByskovLDidriksenM (2001) Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity. Eur J Pharmacol422: 77–81.
58.
HorgerBATaylorJRElsworthJD (1994) Preexposure to, but not cotreatment with, the neurotensin antagonist SR 48692 delays the development of cocaine sensitization. Neuropsychopharmacology11: 215–222.
59.
IversenLLNicollRAValeWW (1978) Neurobiology of peptides. Neurosci Res Program Bull16: 209–370.
60.
KalivasPWDuffyP (1990) Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. J Neurosci10: 2940–2949.
61.
KalivasPWMillerJS (1984) Neurotensin neurons in the ventral tegmental area project to the medial nucleus accumbens. Brain Res300: 157–160.
62.
KalivasPWTaylorS (1985) Behavioral and neurochemical effect of daily injection with neurotensin into the ventral tegmental area. Brain Res358: 70–76.
63.
KalivasPWWeberB (1988) Amphetamine injection into the ventral mesencephalon sensitizes rats to peripheral amphetamine and cocaine. J Pharmacol Exp Ther245: 1095–1102.
64.
KalivasPWBurgessSKNemeroffCB (1983) Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. Neuroscience8: 495–505.
65.
KalivasPWNemeroffCBPrangeAJJr (1984) Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. Neuroscience11: 919–930.
66.
KatsanosGSAnogianakiACastellaniML (2008) Biology of neurotensin: Revisited study. Int J Immunopathol Pharmacol21: 255–259.
67.
KempadooKATourinoCChoSL (2013) Hypothalamic neurotensin projections promote reward by enhancing glutamate transmission in the VTA. J Neurosci33: 7618–7626.
68.
KinkeadBNemeroffCB (2004) Neurotensin, schizophrenia and antipsychotic drug action. Int Rev Neurobiol59: 327–349.
69.
KitabgiP (2006) Prohormone convertases differentially process pro-neurotensin/neuromedin N in tissues and cell lines. J Mol Med84: 628–634.
70.
KitabgiP (2010) Neurotensin and neuromedin N are differentially processed from a common precursor by prohormone convertases in tissues and cell lines. Results Probl Cell Differ50: 85–96.
71.
KitabgiPCarrawayRLeemanSE (1976) Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin. J Biol Chem251: 7053–7058.
72.
KitabgiPDe NadaiFRovèreC (1992) Biosynthesis, maturation, release, and degradation of neurotensin and neuromedin N. Ann NY Acad Sci668: 30–42.
Konstantinopol’skiĭMACherniakovaIVKudrinVS (2013) [Neurotensin NT (8–13) dipeptide analog dilept increases the pain threshold and decreases the severity of morphine withdrawal syndrome in rats]. Eksp Klin Farmakol76: 6–11.
75.
LaCrosseALOliveMF (2013) Neuropeptide systems and schizophrenia. CNS Neurol Disord Drug Targets12: 619–632.
76.
LászlóKTóthKKertesE (2010) The role of neurotensin in positive reinforcement in the rat central nucleus of amygdala. Behav Brain Res208: 430–435.
77.
LeeMRHintonDJSongJY (2010) Neurotensin receptor Type 1 regulates ethanol intoxication and consumption in mice. Pharmacol Biochem Behav95: 235–241.
78.
LeeMRHintonDJUnalSS (2011) Increased ethanol consumption and preference in mice lacking neurotensin receptor Type 2. Alcohol Clin Exp Res35: 99–107.
79.
LévesqueKLamarcheCRompréPP (2008) Evidence for a role of endogenous neurotensin in the development of sensitization to the locomotor stimulant effect of morphine. Eur J Pharmacol594: 132–138.
80.
LiXMFerraroLTanganelliSO’ConnorWT (1995) Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: A receptor binding and microdialysis study. J Neural Transm Gen Sect102: 125–137.
81.
LiangYBoulesMShawAM (2008) Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain. Brain Res1231: 6–15.
82.
LopakVErbS (2005) Activation of central neurotensin receptors reinstates cocaine seeking in the rat: Modulation by a D1/D5, but not D2/D3, receptor antagonist. Psychopharmacology182: 297–304.
83.
LuttingerDNemeroffCBPrangeAJJr (1982) The effects of neuropeptides on discrete-trial conditioned avoidance responding. Brain Res237: 183–192.
84.
McBrideWJMurphyJMIkemotoS (1999) Localization of brain reinforcement mechanisms: Intracranial self-administration and intracranial place-conditioning studies. Behav Brain Res101: 129–152.
85.
Marie-ClaireCPalminteriSRomualdiP (2008) Effects of the selective neurotensin antagonist SR 142948A on 3,4-methylenedioxymethamphetamine-induced behaviours in mice. Neuropharmacology54: 1107–1111.
86.
MazellaJVincentJP (2006) Functional roles of the NTS2 and NTS3 receptors. Peptides27: 2469–2475.
87.
MeisenbergGSimmonsWH (1985) Motor hypoactivity induced by neurotensin and related peptides in mice. Pharmacol Biochem Behav22: 189–193.
88.
MerchantKMDobieDJFillouxFM (1994) Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. J Pharmacol Exp Ther271: 460–471.
89.
MinaminoNKangawaKMatsuoH (1984) Neuromedin N: A novel neurotensin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun122: 542–549.
90.
MyersRMShearmanJWKitchingMO (2009) Cancer, chemistry and the cell: Molecules that interact with the neurotensin receptors. ACS Chem Biol4: 503–525.
91.
NemeroffCB (1980) Neurotensin: Perchance an endogenous neuroleptic?Biol Psychiatry15: 283–302.
92.
NemeroffCBLuttingerDHernandezDE (1983) Interactions of neurotensin with brain dopamine systems: Biochemical and behavioral studies. J Pharmacol Exp Ther225: 337–345.
93.
NouelDDubucIKitabgiP (1990) Centrally administered [D-Trp11] neurotensin, as well as neurotensin protected from inactivation by thiorphan, modifies locomotion in rats in a biphasic manner. Peptides11: 551–555.
94.
OllmannTPéczelyLLászlóK (2015) Positive reinforcing effect of neurotensin microinjection into the ventral pallidum in conditioned place preference test. Behav Brain Res278: 470–475.
95.
PanayiFColussi-MasJLambás-SeñasL (2005) Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization. Neuropsychopharmacology30: 871–879.
96.
PanayiFDorsoELambás-SeñasL (2002) Chronic blockade of neurotensin receptors strongly reduces sensitized, but not acute, behavioral response to D-amphetamine. Neuropsychopharmacology26: 64–74.
97.
PelapratD (2006) Interactions between neurotensin receptors and G proteins. Peptides27: 2476–2487.
98.
PetrieKASchmidtDBubserM (2005) Neurotensin activates GABAergic interneurons in the prefrontal cortex. J Neurosci25: 1629–1636.
99.
PhillipsTJShenEH (1996) Neurochemical bases of locomotion and ethanol stimulant effects. Int Rev Neurobiol39: 243–282.
100.
PicciottoMRCorrigallWA (2002) Neuronal systems underlying behaviors related to nicotine addiction: Neural circuits and molecular genetics. J Neurosci22: 3338–3341.
101.
PierceRCKalivasPW (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev25: 192–216.
102.
PilotteNSMitchellWMSharpeLG (1991) Chronic cocaine administration and withdrawal of cocaine modify neurotensin binding in rat brain. Synapse9:111–120.
103.
RichardFBarrosoSMartinezJ (2001) Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol Pharmacol60: 1392–1398.
104.
RichelsonEBoulesMFredricksonP (2003) Neurotensin agonists: Possible drugs for treatment of psychostimulant abuse. Life Sci73: 679–690.
105.
RobinsonTEBerridgeKC (1993) The neural basis of drug craving: An incentive sensitization theory of addiction. Brain Res Brain Res Rev18: 247–291.
106.
RobledoPMaldonadoRKoobGF (1993) Neurotensin injected into the nucleus accumbens blocks the psychostimulant effects of cocaine but does not attenuate cocaine self-administration in the rat. Brain Res622: 105–112.
107.
RompréPP (1995) Psychostimulant-like effect of central microinjection of neurotensin on brain stimulation reward. Peptides16: 1417–1420.
108.
RompréPP (1997) Repeated activation of neurotensin receptors sensitizes to the stimulant effect of amphetamine. Eur J Pharmacol328: 131–134.
109.
RompréPPBaucoP (2006) Neurotensin receptor activation sensitizes to the locomotor stimulant effect of cocaine: A role for NMDA receptors. Brain Res1085: 77–86.
110.
RompréPPBoyeSM (1993) Opposite effects of mesencephalic microinjections of cholecystokinin octapeptide and neurotensin-(1-13) on brain stimulation reward. Eur J Pharmacol232: 299–303.
111.
RompréPPPerronS (2000) Evidence for a role of endogenous neurotensin in the initiation of amphetamine sensitization. Neuropharmacology39: 1880–1892.
112.
RompréPPBaucoPGrattonA (1992) Facilitation of brain stimulation reward by mesencephalic injections of neurotensin-(1-13). Eur J Pharmacol211: 295–303.
113.
RompréPPBoyeSMMoisanJ (1998) Activation of neurotensin receptors in the prefrontal cortex stimulates midbrain dopamine cell firing. Eur J Pharmacol341: 169–172.
114.
RostèneWBrouardADanaC (1992) Interaction between neurotensin and dopamine in the brain. Morphofunctional and clinical evidence. Ann NY Acad Sci668: 217–231.
115.
RouibiKRompréPP (2014) Role of context in neurotensin-induced sensitization to the locomotor stimulant effect of amphetamine. Peptides58: 103–107.
116.
Saint-GelaisFJompheCTrudeauLE (2006) The role of neurotensin in central nervous system pathophysiology: What is the evidence?J Psychiatry Neurosci31: 229–245.
117.
SarhanSHitchcockJMGrauffelCA (1997) Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Peptides18: 1223–1227.
118.
SellingsLHClarkePB (2003) Segregation of amphetamine reward and locomotor stimulation between nucleus accumbens medial shell and core. J Neurosci23: 6295–6303.
119.
SesackSRPickelVM (1992) Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol320: 145–160.
ShillingPDRichelsonEFeifelD (2003) The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behav Brain Res143: 7–14.
122.
SkoogKMCainSTNemeroffCB (1986) Centrally administered neurotensin suppresses locomotor hyperactivity induced by d-amphetamine but not by scopolamine or caffeine. Neuropharmacology25: 777–782.
123.
SteinbergRBrunPSouilhacJ (1995) Neurochemical and behavioural effects of neurotensin vs D-Tyr11 neurotensin on mesolimbic dopaminergic function. Neuropeptides28: 43–50.
124.
SteketeeJDKalivasPW (2011) Drug wanting: Behavioral sensitization and relapse to drug-seeking behavior. Pharmacol Rev63; 348–365.
125.
TanganelliSAntonelliTTomasiniMC (2012) Relevance of dopamine D(2)/neurotensin NT1 and NMDA/neurotensin NT1 receptor interaction in psychiatric and neurodegenerative disorders. Curr Med Chem19: 304–316.
126.
TanganelliSO’ConnorWTFerraroL (1994) Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neuroscience60: 649–657.
127.
TorregrossaMMKalivasPW (2008) Neurotensin in the ventral pallidum increases extracellular gamma-aminobutyric acid and differentially affects cue- and cocaine-primed reinstatement. J Pharmacol Exp Ther325: 556–566.
128.
Tyler-McMahonBMBoulesMRichelsonE (2000) Neurotensin: Peptide for the next millennium. Regul Pept93: 125–136.
129.
TzschentkeTM (2007) Measuring reward with the conditioned place preference (CPP) paradigm: Update of the last decade. Addict Biol12: 227–462.
130.
TzschentkeTMSchmidtWJ (2003) Glutamatergic mechanisms in addiction. Mol Psychiatry8: 373–382.
131.
VadnieCAHintonDJChoiS (2014) Activation of neurotensin receptor Type 1 attenuates locomotor activity. Neuropharmacology85: 482–492.
132.
VanderschurenLJKalivasPW (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: A critical review of preclinical studies. Psychopharmacology151: 99–120.
133.
VincentJPMazellaJKitabgiP (1999) Neurotensin and neurotensin receptors. Trends Pharmacol Sci20: 302–309.
134.
VitaNOury-DonatFChalonP (1998). Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur J Pharmacol360: 265–272.
135.
Von EulerG (1991) Biochemical characterization of the intramembrane interaction between neurotensin and dopamine D2 receptors in the rat brain. Brain Res561: 93–98.
136.
Von EulerGFuxeK (1987) Neurotensin reduces the affinity of D2-dopamine receptors in rat striatal membranes. Acta Physiol Scand131: 625–626.
137.
Von EulerGMeisterBHökfeltT (1990) Intraventricular injection of neurotensin reduces dopamine D2 agonist binding in rat forebrain and intermediate lobe of the pituitary gland. Relationship to serum hormone levels and nerve terminal coexistence. Brain Res531: 253–262.
138.
Von EulerGVan der PloegIFredholmBB (1991) Neurotensin decreases the affinity of dopamine D2 agonist binding by a G protein-independent mechanism. J Neurochem56: 178–183.
139.
WachiMFujimakiMNakamuraH (1996) Effects of ethanol administration on brain neurotensin-like immunoreactivity in rats. Acta Neurol Scand93: 211–214.
140.
WerkmanTRKruseCGNievelsteinH (2000) Neurotensin attenuates the quinpirole-induced inhibition of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area. Neuroscience95: 417–423.
141.
WiddowsonPS (1987) The effect of neurotensin, TRH and the delta-opioid receptor antagonist ICI 174864 on alcohol-induced narcosis in rats. Brain Res424: 281–289.
142.
WiseRABozarthMA (1987) A psychomotor stimulant theory of addiction. Psychol Rev94: 469–492.
143.
ZahmDSHeimerL (1988) Ventral striatopallidal parts of the basal ganglia in the rat: I. Neurochemical compartmentation as reflected by the distributions of neurotensin and substance P immunoreactivity. J Comp Neurol272: 516–535.
144.
ZahmDSHeimerL (1990) Two transpallidal pathways originating in the rat nucleus accumbens. J Comp Neurol302: 437–446.
